Determining biomarkers
PTB-News 2.2022
02.05.2022
A patent application has been filed for accurate, platform-independent and calibration-free measurement procedures performed on xenon atoms. Developed by PTB, such procedures are an innovative technology for quantifying biomarkers that use xenon-binding antibodies as biosensors. This approach is an alternative to the radioactive or fluorophore markers used to date; it could also prove interesting for vaccine development. (Technology Offers 341 + 535)
Advantages
high detection sensitivity and accuracy
calibration-free measurement
platform-independent results
use of biosensors
Contact person for questions about technology transfer
Andreas Barthel, Phone: +49 531 592-8307, andreas.barthel(at)ptb.de, www.technologietransfer.ptb.de/en